Dec 13, 2013 by Max Macaluso and Michael Olsen, CFAWill Obamacare Crush These Health Care Giants?The uncertainty surrounding the Affordable Care Act looms large, but will managed care stocks like WellPoint and UnitedHealth continue to outperform the market?
Dec 11, 2013 by Max Macaluso and Simon EricksonWhat OncoMed's Deal With Celgene Means for InvestorsA look at Celgene's latest deal with OncoMed, a small biotech that went public just a few months ago.
Dec 1, 2013 by Max Macaluso3 Drugs That Changed Medicine (and Were Discovered by Accident)Pfizer and Allergan market game-changing drugs that were discovered by accident -- but how did it happen?
Nov 29, 2013 by Max MacalusoAstraZeneca Stock: 3 Things to KnowWhat should investors know about drugmaker AstraZeneca (NYSE: AZN) before buying or selling?
Nov 29, 2013 by Max MacalusoTeva Stock: 3 Key Things to KnowWhat key issues should investors look at when analyzing Teva's stock?
Nov 27, 2013 by Max Macaluso and David GardnerMotley Fool Co-Founder David Gardner on Investing for BeginnersOne of our head Fools discusses why some people are fearful of managing their own money, and how The Motley Fool is helping.
Nov 26, 2013 by Max Macaluso and Simon EricksonNovo Nordisk's Biggest Strength and WeaknessIs Novo Nordisk's (NYSE: NVO) diabetes treatment-focused strategy wise, or should the company diversify?
Nov 25, 2013 by Max Macaluso and David GardnerKickstarter and the "Long Tail"Motley Fool co-founder David Gardner's thoughts on revolutionary platform Kickstarter.
Nov 24, 2013 by Max Macaluso and David GardnerHow Investors Can Look Beyond the NumbersToday’s business leaders lead lives that are public in ways we couldn’t have imagined 25 years ago, making investors’ job just a little easier.
Nov 19, 2013 by Max Macaluso"Invest in What You Know"? Maybe, Maybe Not.David Gardner offers his thoughts on how to get your feet wet when investing in an unfamiliar industry.
Nov 19, 2013 by Max MacalusoShould You Fear Stocks in the Health-Care Space?Motley Fool co-founder David Gardner discusses health-care stocks and two options for investors who fear them.
Nov 14, 2013 by Max Macaluso and David GardnerMotley Fool Co-Founder David Gardner's Approach to "Fearless" InvestingMotley Fool Co-Founder and Chief Rule Breaker David Gardner discusses his brand of "fearless" investing, how to look at stocks in the biotech industry, his investing philosophy -- and yes, even Kickstarter and the Pebble smartwatch.
Oct 30, 2013 by Max Macaluso and Alison SouthwickDown 13%: More Bad Luck for Amarin Corporation plcShares of Amarin, which have already been crushed this month, dropped another 13% today. What was behind the plunge?
Oct 30, 2013 by Max Macaluso and Alison SouthwickDown 8%: What's Behind Teva's Massive Plunge?Teva Pharmaceuticals is down 8% today, but it's not directly due to competition in the multiple sclerosis space from new drugs like Biogen's Tecfidera. To find out what happened and what may lie ahead for Teva, watch this video.
Oct 28, 2013 by Max Macaluso, Dave Williamson, and Alison SouthwickAnother Big Win for Big Biotech Biogen?Biogen reported its third-quarter results, but was it all good news for the big biotech company?
Oct 28, 2013 by Max Macaluso, Dave Williamson, and Alison SouthwickWhy This Dow Heavyweight Sank on EarningsWhy did shares of Dow component Merck drop as other drugmakers, such as Bristol-Myers Squibb and AstraZeneca, rose today?
Oct 18, 2013 by Max Macaluso, Dave Williamson, and Alison SouthwickWhat Was Behind Ariad's 40% Drop?Ariad Pharmaceuticals has already dropped significantly this week --- what was behind today's move?
Oct 18, 2013 by Max Macaluso, Dave Williamson, and Alison SouthwickWhat Was Behind Anacor's 28% Climb?Why did shares of biotech company Anacor surge today?
Oct 18, 2013 by Max Macaluso, Dave Williamson, and Alison SouthwickThe Next Cholesterol-Fighting Blockbuster Drug?Regeneron and its partner Sanofi reported results from a late-stage trial for their new cholesterol-lowering drug. Can this be the next Lipitor?
Oct 16, 2013 by Max Macaluso, Dave Williamson, and Alison SouthwickAbbott's Earnings Made EasyWhat were the takeaways from Abbott's third-quarter results?
